DOCSLIB.ORG

PDE3A Downregulation in Chemioresistant NSCLC the Cell Counting Kit-8 (Dojindo, Kumamoto, Demethylation Restores PDE3A Japan) According to Manufacturer’S Instruction

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PDE3A Downregulation in Chemioresistant NSCLC the Cell Counting Kit-8 (Dojindo, Kumamoto, Demethylation Restores PDE3A Japan) According to Manufacturer’S Instruction European Review for Medical and Pharmacological Sciences 2017; 21: 2635-2641 PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response F.-M. TIAN1, C.-Y. ZHONG2, X.-N. WANG3, Y. MENG4 1Respiratory Medicine, The People’s Hospital of Pingyi Country, Linyi, Shandong, China 2Department of Cardiology, Zoucheng People’s Hospital, Zoucheng, Shandong, China 3Clinical College, Weifang Medical University, Weifang, Shandong, China 4Respiratory Medicine, Shanxian Central Hospital, Heze, Shandong, China Feng-Mei Tian and Chong-Yuan Zhong contributed equally to this study Abstract. – OBJECTIVE: In this study, we PDE3A expression is associated with better aimed to investigate the mechanism of PDE3A OS and PFS in patients with adenocarcinoma, downregulation in chemoresistant non-small but not in patients with squamous cell carci- cell lung cancer (NSCLC) cells, its functional noma. role in chemotherapy response and association with survival outcomes. Key Words: MATERIALS AND METHODS: The raw data of PDE3A, Methylation, Cisplatin, NSCLC. GDS5247 was downloaded from GEO datasets and reanalyzed. The expression of PDE3A in pa- tients with NSCLC and its DNA methylation sta- tus were analyzed in NSCLC cohort in TCGA da- Introduction tabase. Cisplatin resistant A549/Cis cells and the parental A549 cells were used as the in vi- tro cell model. The association between PDE3A Non-small cell lung cancer (NSCLC) is one of expression and overall survival (OS) and pro- the leading causes of cancer-related deaths across 1 gression-free survival (PFS) in NSCLC patients the world . For the patients with advanced NSCLC, with adenocarcinoma or squamous cell carci- cisplatin based chemotherapy is still the most ef- noma, as well as the median OS and PFS, were fective therapeutic strategy2. However, cancer assessed by Kaplan-Meier curves using Ka- usually develops chemoresistance after repetitive plan-Meier plotter. 3 RESULTS: administration of chemotherapeutic drugs . The- PDE3A was significantly downregu- refore, it is necessary to understand the molecular lated in chemoresistant NSCLC cells. Heat map of PDE3A expression and methylation in NS- mechanisms underlying the resistance. Some re- CLC patient cohort in TCGA database indicated cent studies found that epigenetic alterations are a negative association between PDE3A expres- closely related to chemoresistance, such as DNA sion and DNA methylation in lung adenocarcino- methylation4,5. The key enzymes involved in DNA ma. A549/Cis cells treated with 5-AZA-dC, a de- methylation include de novo methyltransferases methylation reagent, had significantly restored DNMT3A and DNMT3B and DNA methylation PDE3A expression. High PDE3A expression was maintenance methyltransferase DNMT16, which associated with favorable OS (HR: 0.53, 95% CI: are usually upregulated in multiple chemoresistant 0.41-0.68, p<0.0001) and PFS (HR: 0.54, 95% CI: 7,8 0.39-0.75, p<0.001) in patients with adenocarci- cancer cell lines . Hypermethylation of DKK3, noma. However, in patients with squamous cell RUNX3 and SLFN11 directly confer increa- carcinoma, high PDE3A expression was associ- sed chemoresistance to human NSCLC cells8-10. ated with unfavorable OS (HR: 1.56, 95% CI: 1.08- Cyclic nucleotide phosphodiesterases (PDEs) is a 2.24, p=0.017) and PFS (HR: 1.83, 95% CI: 1.02- family of the enzyme that breaks phosphodiester 3.29, p=0.04). CONCLUSIONS: bonds, including the phosphodiester bond in the PDE3A is downregulated in second messenger cAMP11. In fact, the balance of chemoresistant NSCLC cells due to DNA hy- permethylation. Enforced PDE3A expression intracellular cAMP level is mainly regulated by can sensitize A549/Cis cells to cisplatin. High adenylate cyclases (cAMP-generating enzymes) Corresponding Author: Ya Meng, MD; e-mail: [email protected] 2635 F.-M. Tian, C.-Y. Zhong, X.-N. Wang, Y. Meng and PDEs (cAMP-degrading enzymes)12. There- Resources (Beijing, China). The cells were cul- fore, PDEs are important modulators of cellular tured in RPMI-1640 medium supplemented with responses to diverse extracellular stimuli13. Pre- 10% FBS, 100 μg/mL penicillin, and 100 U/mL vious studies reported that the members of pho- streptomycin. sphodiesterase 3 (PDE3), including PDE3A and PDE3B are involved in regulation of cancer cell Cell Transfection invasion and cell motility14,15. The PDE3 inhibi- The PDE3A human Lentifect™ purified lenti- tor, such as cilostazol, can inhibit DNA synthesis viral particles and the empty control vector were and cell viability in some lung cancer cell lines16. obtained from Genecopoeia (Rockville, MD, PDE3A depletion leads to 6-(4-(diethylamino)- USA). A549/Cis cells were infected with the len- 3-nitrophenyl)-5-methyl-4,5-dihydropyridazin- tiviral particles or the negative controls in the pre- 3(2H)-one (DNMDP) resistance in hundreds of sence of polybrene. cancer cell lines17, suggesting that PDE3A may play an important role in cancer cell responses Western Blot Assay to chemotherapeutic regents. In this study, by In brief, the cell samples were lysed to extract reanalysis of one previous microarray, we found total protein. Then the protein samples were that PDE3A is downregulated in chemoresistant denatured and loaded in 10% sodium dodecyl NSCLC cells. Also, we demonstrated that PDE3A sulphate-polyacrylamide gel electrophoresis downregulation is a result of DNA methylation, (SDS-PAGE) for separation. After that, the pro- while PDE3A overexpression sensitized A549/Cis teins were transferred to a polyvinylidene fluo- cells to cisplatin. The following data mining of ride (PVDF) membrane. Then, the membranes available annotated microarray data showed that were incubated with primary antibodies against high PDE3A expression is associated with better PDE3A (ab169534, Abcam, Cambridge, MA, overall survival (OS) and progression-free survi- USA) and β-actin (ab3280, Abcam). After the val (PFS) in patients with adenocarcinoma, but incubation, membranes were washed and further not in patients with squamous cell carcinoma. incubated with secondary antibodies coupled to HRP. Then, the protein bands were visualized by using the SuperSignal™ West Femto Chemi- Materials and Methods luminescent Substrate (Pierce Biotechnology, Rockford, IL, USA) according to manufacturer’s Bioinformatic Data Mining instruction. One previous study18 compared the transcrip- tional profiles between cisplatin-resistant H460 QRT-PCR Analysis NSCLC cells and the parental H460 cells by using Total RNAs in the cell samples were extracted the Affymetrix Human Gene 1.0 ST Array. The raw using the Trizol Reagent (Invitrogen, Carlsbad, data of this microarray was downloaded from GEO CA, USA) and were reverse-transcribed to get datasets (accession No. GDS5247) and reanalyzed. cDNA using the iScript cDNA Synthesis kit (Bio- The expression of PDE3A in patients with NSCLC Rad, Hercules, CA, USA). Then, PDE3A was me- and the corresponding DNA methylation status asured using qRT-PCR analysis with the following were analyzed using the NSCLC cohort in TCGA primers (F, 5’-TTGATGCCAGGAAAATGGAT-3’ database, using the UCSC Xena browser (http:// and R, 5’-CCTTCTCCTCGTCCTCTTCC-3’) and xena.ucsc.edu/). The association between PDE3A the SYBR® Select Master Mix (Applied Biosy- expression and OS and PFS in NSCLC patients with stems, Foster City, CA, USA) in an ABI 7900HT adenocarcinoma or squamous cell carcinoma, as Fast Real-time PCR System (Applied Biosystems, well as the median OS and PFS, were assessed by Foster City, CA, USA). GAPDH was detected as drawing Kaplan-Meier curves using Kaplan-Meier the endogenous control. Plotter, which is an online survival analysis software to assess the prognostic value of biomarkers using Cell Counting Kit-8 (CCK-8) Assay transcriptomic data of 2435 NSCLC patients19. A549 cells and A549/Cis cells with or wi- thout enforced PDE3A expression were plated Cell Culture and Transfection onto 96‑well cell culture plates at a density of 2 The human NSCLC cell line A549 and the cor- x 104 cells/well. Then, the cells were treated with responding cisplatin resistant A549/Cis cells were varying concentrations of cisplatin for 72 h. After obtained from China infrastructure of Cell Line the treatment, cell viability was measured using 2636 PDE3A downregulation in chemioresistant NSCLC the Cell Counting Kit-8 (Dojindo, Kumamoto, Demethylation Restores PDE3A Japan) according to manufacturer’s instruction. Expression in A549/Cis Cells Briefly, CCK-8 solution was added to each well Then, we explored the heat map of PDE3A and the plate was placed in a cell incubator for 4 expression and methylation in NSCLC patient h. Cell viability was reflected by the absorbance cohort in TCGA database. The results indicated at 450 nm determined by a 96-well spectropho- that increased DNA methylation might be as- tometry. IC50 value was determined by creating sociated with decreased PDE3A expression in dose-response curves. lung adenocarcinoma (Figure 2A, black frame), but not in lung squamous cell carcinoma (Figure Flow Cytometric Analysis of Active 2A). Then, we investigated PDE3A expression in Caspase-3 cisplatin resistant lung adenocarcinoma cell line A549/Cis cells with PDE3A overexpression A549/Cis cells and in the parent A549 cells. The alone or in combination with cisplatin treatment results showed that A549/Cis cells had signifi- (50 μmol/L) for 48 h were subjected to flow cyto- cantly lower PDE3A expression at both mRNA metric analysis of active caspase-3 using the Ga- and protein levels (Figure 2B). A549/Cis cells spGLOW ™ Fluorescein Active Caspase-3 Stai- treated with 5-AZA-dC, a demethylation reagent, ning Kit (Biovision, Mountain View, CA, USA) had significantly restored PDE3A expression (Fi- according to the manufacturer’s protocol. Fluo- gure 2C). rescence was examined by a FACSCalibur (BD Biosciences, San Jose, CA, USA). Enforced PDE3A Expression Sensitizes A549/Cis Cells to Cisplatin Statistical Analysis Then, we investigated the functional role of Data were presented as means ± SD. All analy- PDE3A in cell response to cisplatin. A549/Cis cel- ses were performed with SPSS19 software packa- ls were transfected with lentiviral PDE3A expres- ge (SPSS Inc., Chicago, IL, USA).
Load more

Recommended publications
  • Characterization of Cyclic Nucleotide Phosphodiesterase Isoenzymes in the Human Ureter and Their Functional Role in Vitro
    World J Urol (1994) 12:286-291 WorldUrology Journal of © Springer-Verlag 1994 Characterization of cyclic nucleotide phosphodiesterase isoenzymes in the human ureter and their functional role in vitro A. Taher 1, R Schulz-Knappe 2, M. Meyer 1, 2, M. Truss 1, 2, W.-G. Forssmann 2, C. G. Stief l, and U. Jonas 1 Department of Urology, Medical School, Hannover, Germany 2 Lower Saxony Institute for Peptide Research, Medical School, Hannover, Germany Summary. An increase in cyclic nucleotide monophos- cial concretion and, thus, to allow increased fluid flow be- phate levels is suggested to play a prominent role in yond the concretion. mediating smooth-muscle relaxation. Cyclic nucleotide Many drugs have been used in ureteral colic manage- phosphodiesterase (PDE) influences smooth-muscle tone ment [3], but the drug that can relief pain and facilitate by decreasing the level of cyclic nucleotides. At present, stone passage with minimal systemic side effects is miss- five different families of isoenzymes of PDE exist that ing. One family of drugs used in the treatment of ureteral show a distinct species- and organ-specific distribution. colics is the prostaglandin synthetase inhibitor [4]. These Our study was done to evaluate the existence of specific drugs not only relieve the pain but also facilitate stone PDE isoenzymes and its functional role in human ureteral passage [5]. The most effective mode of administration is tissue. Normal ureteral tissue was homogenized and the intravenous route, but in 55% of cases, side effects oc- centrifuged and the supernatant fraction was separated us- cur. However, since these drugs also decrease the renal ing anioin-exchange diethylaminoethyl (DEAE)-Sephacel blood flow, they may induce renal failure, especially in chromatography.
    [Show full text]
  • Analyses of PDE-Regulated Phosphoproteomes Reveal Unique and Specific Camp-Signaling Modules in T Cells
    Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells Michael-Claude G. Beltejara, Ho-Tak Laua, Martin G. Golkowskia, Shao-En Onga, and Joseph A. Beavoa,1 aDepartment of Pharmacology, University of Washington, Seattle, WA 98195 Contributed by Joseph A. Beavo, May 28, 2017 (sent for review March 10, 2017; reviewed by Paul M. Epstein, Donald H. Maurice, and Kjetil Tasken) Specific functions for different cyclic nucleotide phosphodiester- to bias T-helper polarization toward Th2, Treg, or Th17 pheno- ases (PDEs) have not yet been identified in most cell types. types (13, 14). In a few cases increased cAMP may even potentiate Conventional approaches to study PDE function typically rely on the T-cell activation signal (15), particularly at early stages of measurements of global cAMP, general increases in cAMP- activation. Recent MS-based proteomic studies have been useful dependent protein kinase (PKA), or the activity of exchange in characterizing changes in the phosphoproteome of T cells under protein activated by cAMP (EPAC). Although newer approaches various stimuli such as T-cell receptor stimulation (16), prosta- using subcellularly targeted FRET reporter sensors have helped glandin signaling (17), and oxidative stress (18), so much of the define more compartmentalized regulation of cAMP, PKA, and total Jurkat phosphoproteome is known. Until now, however, no EPAC, they have limited ability to link this regulation to down- information on the regulation of phosphopeptides by PDEs has stream effector molecules and biological functions. To address this been available in these cells. problem, we have begun to use an unbiased mass spectrometry- Inhibitors of cAMP PDEs are useful tools to study PKA/EPAC- based approach coupled with treatment using PDE isozyme- mediated signaling, and selective inhibitors for each of the 11 PDE – selective inhibitors to characterize the phosphoproteomes of the families have been developed (19 21).
    [Show full text]
  • Phosphodiesterase Inhibitors: Their Role and Implications
    International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.1, No.4, pp 1148-1160, Oct-Dec 2009 PHOSPHODIESTERASE INHIBITORS: THEIR ROLE AND IMPLICATIONS Rumi Ghosh*1, Onkar Sawant 1, Priya Ganpathy1, Shweta Pitre1 and V.J.Kadam1 1Dept. of Pharmacology ,Bharati Vidyapeeth’s College of Pharmacy, University of Mumbai, Sector 8, CBD Belapur, Navi Mumbai -400614, India. *Corres.author: rumi 1968@ hotmail.com ABSTRACT: Phosphodiesterase (PDE) isoenzymes catalyze the inactivation of intracellular mediators of signal transduction such as cAMP and cGMP and thus have pivotal roles in cellular functions. PDE inhibitors such as theophylline have been employed as anti-asthmatics since decades and numerous novel selective PDE inhibitors are currently being investigated for the treatment of diseases such as Alzheimer’s disease, erectile dysfunction and many others. This review attempts to elucidate the pharmacology, applications and recent developments in research on PDE inhibitors as pharmacological agents. Keywords: Phosphodiesterases, Phosphodiesterase inhibitors. INTRODUCTION Alzheimer’s disease, COPD and other aliments. By cAMP and cGMP are intracellular second messengers inhibiting specifically the up-regulated PDE isozyme(s) involved in the transduction of various physiologic with newly synthesized potent and isoezyme selective stimuli and regulation of multiple physiological PDE inhibitors, it may possible to restore normal processes, including vascular resistance, cardiac output, intracellular signaling selectively, providing therapy with visceral motility, immune response (1), inflammation (2), reduced adverse effects (9). neuroplasticity, vision (3), and reproduction (4). Intracellular levels of these cyclic nucleotide second AN OVERVIEW OF THE PHOSPHODIESTERASE messengers are regulated predominantly by the complex SUPER FAMILY superfamily of cyclic nucleotide phosphodiesterase The PDE super family is large, complex and represents (PDE) enzymes.
    [Show full text]
  • Identification and Analysis of Hepatitis C Virus NS3 Helicase Inhibitors Using Nucleic Acid Binding Assays Sourav Mukherjee1, Alicia M
    Published online 27 June 2012 Nucleic Acids Research, 2012, Vol. 40, No. 17 8607–8621 doi:10.1093/nar/gks623 Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays Sourav Mukherjee1, Alicia M. Hanson1, William R. Shadrick1, Jean Ndjomou1, Noreena L. Sweeney1, John J. Hernandez1, Diana Bartczak1, Kelin Li2, Kevin J. Frankowski2, Julie A. Heck3, Leggy A. Arnold1, Frank J. Schoenen2 and David N. Frick1,* 1Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, 2University of Kansas Specialized Chemistry Center, University of Kansas, 2034 Becker Dr., Lawrence, KS 66047 and 3Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY 10595, USA Received March 26, 2012; Revised May 30, 2012; Accepted June 4, 2012 Downloaded from ABSTRACT INTRODUCTION Typical assays used to discover and analyze small All cells and viruses need helicases to read, replicate and molecules that inhibit the hepatitis C virus (HCV) repair their genomes. Cellular organisms encode NS3 helicase yield few hits and are often con- numerous specialized helicases that unwind DNA, RNA http://nar.oxfordjournals.org/ founded by compound interference. Oligonucleotide or displace nucleic acid binding proteins in reactions binding assays are examined here as an alternative. fuelled by ATP hydrolysis. Small molecules that inhibit After comparing fluorescence polarization (FP), helicases would therefore be valuable as molecular homogeneous time-resolved fluorescence (HTRFÕ; probes to understand the biological role of a particular Cisbio) and AlphaScreenÕ (Perkin Elmer) assays, helicase, or as antibiotic or antiviral drugs (1,2). For an FP-based assay was chosen to screen Sigma’s example, several compounds that inhibit a helicase Library of Pharmacologically Active Compounds encoded by herpes simplex virus (HSV) are potent drugs in animal models (3,4).
    [Show full text]
  • Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
    International Journal of Molecular Sciences Review Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19? Mauro Giorgi 1,*, Silvia Cardarelli 2, Federica Ragusa 3, Michele Saliola 1, Stefano Biagioni 1, Giancarlo Poiana 1 , Fabio Naro 2 and Mara Massimi 3,* 1 Department of Biology and Biotechnology “Charles Darwin”, Sapienza University of Rome, 00185 Rome, Italy; [email protected] (M.S.); [email protected] (S.B.); [email protected] (G.P.) 2 Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Sapienza University, 00185 Rome, Italy; [email protected] (S.C.); [email protected] (F.N.) 3 Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy; [email protected] * Correspondence: [email protected] (M.G.); [email protected] (M.M.) Received: 10 July 2020; Accepted: 24 July 2020; Published: 27 July 2020 Abstract: In March 2020, the World Health Organization declared the severe acute respiratory syndrome corona virus 2 (SARS-CoV2) infection to be a pandemic disease. SARS-CoV2 was first identified in China and, despite the restrictive measures adopted, the epidemic has spread globally, becoming a pandemic in a very short time. Though there is growing knowledge of the SARS-CoV2 infection and its clinical manifestations, an effective cure to limit its acute symptoms and its severe complications has not yet been found. Given the worldwide health and economic emergency issues accompanying this pandemic, there is an absolute urgency to identify effective treatments and reduce the post infection outcomes. In this context, phosphodiesterases (PDEs), evolutionarily conserved cyclic nucleotide (cAMP/cGMP) hydrolyzing enzymes, could emerge as new potential targets.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,333,354 B1 Schudt (45) Date of Patent: Dec
    USOO6333354B1 (12) United States Patent (10) Patent No.: US 6,333,354 B1 Schudt (45) Date of Patent: Dec. 25, 2001 (54) SYNERGISTIC COMBINATION OF PDE Buerke et al.: “Synergistic platelet inhibitory effect of the INHIBITORS AND ADENYLATE CYCLASE phosphodiesterase inhibitor piroximone and iloprost: Pros AGONSTS OR GUANYL CYCLYSE taglandins in the Cardiovascular System, 1992, 37/suppl. AGONSTS (71–77).* (75) Inventor: Christian Schudt, Constance (DE) O'Grady et al. “A chemically stable analot 9-beta methyl carbacyclin with Similar effects to epoprostenol proStacyclin (73) Assignee: Byk Gulden Lomberg Chemische prostaglandin in I-2 in man” Br J Clin Pharmacol, 18(6). Fabrik GmbH, Constance (DE) 1984 (921-934).* (*) Notice: Subject to any disclaimer, the term of this Crutchley et al. “Effects of Prostacyclin Analogs on the patent is extended or adjusted under 35 Synthesis of Tissue Factor, Tumor Necrosis Facotr-alpha U.S.C. 154(b) by 0 days. and Interleukin-1beta in Human Monocytic THP-1 Cells”, J Pharmacol and Experimental Therapeutics, 271 (1). 1994. (21) Appl. No.: 09/367,850 446-451. (22) PCT Filed: Feb. 24, 1998 Crutchley et al. “Prostacyclin Analogues Inhibit Tissue (86) PCT No.: PCT/EP98/O1047 Factor Expression in the Human Monocytic Cell Line THP-1 Via a Cyclic AMP-Dependent Mechanism” Arterio S371 Date: Aug. 27, 1999 scler. Thromb, 12(6), 1992. 664-670.* S 102(e) Date: Aug. 27, 1999 Turner et al., Br. J. Pharmacol., “Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the (87) PCT Pub. No.: WO98/37894 anaesthetized guinea-pig", (1994), 111, pp.
    [Show full text]
  • Various Subtypes of Phosphodiesterase Inhibitors Differentially Regulate Pulmonary Vein and Sinoatrial Node Electrical Activities
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 19: 2773-2782, 2020 Various subtypes of phosphodiesterase inhibitors differentially regulate pulmonary vein and sinoatrial node electrical activities YUNG‑KUO LIN1,2*, CHEN‑CHUAN CHENG3*, JEN‑HUNG HUANG1,2, YI-ANN CHEN4, YEN-YU LU5, YAO‑CHANG CHEN6, SHIH‑ANN CHEN7 and YI-JEN CHEN1,8 1Department of Internal Medicine, Division of Cardiovascular Medicine, Wan Fang Hospital; 2Department of Internal Medicine, Division of Cardiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11696; 3Division of Cardiology, Chi‑Mei Medical Center, Tainan 71004; 4Division of Nephrology; 5Division of Cardiology, Department of Internal Medicine, Sijhih Cathay General Hospital, New Taipei 22174; 6Department of Biomedical Engineering, National Defense Medical Center, Taipei 11490; 7Heart Rhythm Center and Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217; 8Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11696, Taiwan, R.O.C. Received May 16, 2019; Accepted January 9, 2020 DOI: 10.3892/etm.2020.8495 Abstract. Phosphodiesterase (PDE)3-5 are expressed in 20.7±4.6%, respectively. In addition, milrinone (1 and 10 µM) cardiac tissue and play critical roles in the pathogenesis of induced the occurrence of triggered activity (0/8 vs. 5/8; heart failure and atrial fibrillation. PDE inhibitors are widely P<0.005) in PVs. Rolipram increased PV spontaneous activity used in the clinic, but their effects on the electrical activity by 7.5±1.3‑9.5±4.0%, although this was not significant, and did of the heart are not well understood. The aim of the present not alter SAN spontaneous activity.
    [Show full text]
  • Metabolic Enzyme/Protease
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Metabolic Enzyme/Protease Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. In each pathway, enzymes catalyze the conversion of substrates into structurally similar products. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. Metabolism maintains the living state of the cells and the organism. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. Proteases can not only activate proteins such as cytokines, or inactivate them such as numerous repair proteins during apoptosis, but also expose cryptic sites, such as occurs with β-secretase during amyloid precursor protein processing, shed various transmembrane proteins such as occurs with metalloproteases and cysteine proteases, or convert receptor agonists into antagonists and vice versa such as chemokine conversions carried out by metalloproteases, dipeptidyl peptidase IV and some cathepsins. In addition to the catalytic domains, a great number of proteases contain numerous additional domains or modules that substantially increase the complexity of their functions.
    [Show full text]
  • Therapeutic Opportunities in Colon Cancer Focus on Phosphodiesterase Inhibitors
    Life Sciences 230 (2019) 150–161 Contents lists available at ScienceDirect Life Sciences journal homepage: www.elsevier.com/locate/lifescie Review article Therapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors T ⁎ Ankita Mehta, Bhoomika M. Patel Institute of Pharmacy, Nirma University, Ahmedabad, India ARTICLE INFO ABSTRACT Keywords: Despite novel technologies, colon cancer remains undiagnosed and 25% of patients are diagnosed with meta- Phosphodiesterases static colon cancer. Resistant to chemotherapeutic agents is one of the major problems associated with treating cAMP colon cancer which creates the need to develop novel agents targeting towards newer targets. A phosphodies- cGMP terase is a group of isoenzyme, which, hydrolyze cyclic nucleotides and thereby lowers intracellular levels of Adenylate cyclase cAMP and cGMP leading to tumorigenic effects. Many in vitro and in vivo studies have confirmed increased PDE Guanylate cyclase expression in different types of cancers including colon cancer. cAMP-specific PDE inhibitors increase in- Colon cancer tracellular cAMP that leads to activation of effector molecules-cAMP-dependent protein kinase A, exchange protein activated by cAMP and cAMP gated ion channels. These molecules regulate cellular responses and exert its anticancer role through different mechanisms including apoptosis, inhibition of angiogenesis, upregulating tumor suppressor genes and suppressing oncogenes. On the other hand, cGMP specific PDE inhibitors exhibit anticancer effects through cGMP dependent protein kinase and cGMP dependent cation channels. Elevation in cGMP works through activation of caspases, suppression of Wnt/b-catenin pathway and TCF transcription leading to inhibition of CDK and survivin. These studies point out towards the fact that PDE inhibition is as- sociated with anti-proliferative, anti-apoptotic and anti-angiogenic pathways involved in its anticancer effects in colon cancer.
    [Show full text]
  • Identification of Cancer Cytotoxic Modulators of PDE3A by Predictive Chemogenomics
    Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation de Waal, Luc et al. “Identification of Cancer-Cytotoxic Modulators of PDE3A by Predictive Chemogenomics.” Nature Chemical Biology 12.2 (2015): 102–108. As Published http://dx.doi.org/10.1038/nchembio.1984 Publisher Nature Publishing Group Version Author's final manuscript Citable link http://hdl.handle.net/1721.1/106947 Terms of Use Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. Published as: Nat Chem Biol. 2016 February ; 12(2): 102–108. HHMI Author ManuscriptHHMI Author Manuscript HHMI Author Manuscript HHMI Author Identification of cancer cytotoxic modulators of PDE3A by predictive chemogenomics Luc de Waal1,2, Timothy A. Lewis1, Matthew G. Rees1, Aviad Tsherniak1, Xiaoyun Wu1, Peter S. Choi1,2, Lara Gechijian1, Christina Hartigan1, Patrick W. Faloon1, Mark J. Hickey1, Nicola Tolliday1, Steven A. Carr1, Paul A. Clemons1, Benito Munoz1, Bridget K. Wagner1, Alykhan F. Shamji1, Angela N. Koehler1,3, Monica Schenone1, Alex B. Burgin1, Stuart L. Schreiber1, Heidi Greulich1,2,4,*, and Matthew Meyerson1,2,5,* 1The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA 3Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts 02142, USA 4Department of Medicine, Harvard Medical School, Boston, MA 02115 5Department of Pathology, Harvard Medical School, Boston, MA 02115 Abstract High cancer death rates indicate the need for new anti-cancer therapeutic agents.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Dual PDE34 and PDE4 Inhibitors
    Basic & Clinical Pharmacology & Toxicology Doi: 10.1111/bcpt.12209 MiniReview Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases Katharine H. Abbott-Banner1 and Clive P. Page2 1Verona Pharma plc, London, UK and 2Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (Received 2 December 2013; Accepted 30 January 2014) Abstract: Selective phosphodiesterase (PDE) 4 and dual PDE3/4 inhibitors have attracted considerable interest as potential thera- peutic agents for the treatment of respiratory diseases, largely by virtue of their anti-inflammatory (PDE4) and bifunctional bron- chodilator/anti-inflammatory (PDE3/4) effects. Many of these agents have, however, failed in early development for various reasons, including dose-limiting side effects when administered orally and lack of sufficient activity when inhaled. Indeed, only one selective PDE4 inhibitor, the orally active roflumilast-n-oxide, has to date received marketing authorization. The majority of the compounds that have failed were, however, orally administered and non-selective for either PDE3 (A,B) or PDE4 (A,B,C,D) subtypes. Developing an inhaled dual PDE3/4 inhibitor that is rapidly cleared from the systemic circulation, potentially with sub- type specificity, may represent one strategy to improve the therapeutic index and also exhibit enhanced efficacy versus inhibition of either PDE3 or PDE4 alone, given the potential positive interactions with regard to anti-inflammatory and bronchodilator effects that have been observed pre-clinically with dual inhibition of PDE3 and PDE4 compared with inhibition of either isozyme alone. This MiniReview will summarize recent clinical data obtained with PDE inhibitors and the potential for these drugs to treat COPD and other inflammatory airways diseases such as asthma and cystic fibrosis.
    [Show full text]